WA
INSY

WFG Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

WFG Advisors’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$11K Buy
+900
New +$10.7K ﹤0.01% 1122
2015
Q3 		– Sell
-140
Closed -$5K – 1761
2015
Q2 		$5K Buy
+140
New +$4.36K ﹤0.01% 1364

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

WFG Advisors's INSY Position: Q2 2017 in Review

WFG Advisors opened a new position in Insys Therapeutics, Inc. (INSY) in Q2 2017: 900 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #1122 among its holdings. This is a return to the name: WFG Advisors previously reported a position in INSY as recently as Q2 2015.

WFG Advisors first reported a position in INSY in Q2 2015 and has held it in 2 quarters since. 118 funds tracked by Wall St. Rank hold INSY as of Q2 2017.

  • WFG Advisors held 900 shares of Insys Therapeutics, Inc. worth $11K as of Q2 2017.
  • Insys Therapeutics, Inc. was a new WFG Advisors position in Q2 2017.
  • Insys Therapeutics, Inc. made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1122 holding.
  • WFG Advisors first reported a position in Insys Therapeutics, Inc. in Q2 2015 and has held it in 2 quarters since.
  • 118 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.